1044870-30-5

Basic information

• Product Name: 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazolin-4-one
• Synonyms: 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazolin-4-one
• CAS NO: 1044870-30-5
• Molecular Weight: 326.352
• Mol File: 1044870-30-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(1044870-30-5)
• EPA Substance Registry System: 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(1044870-30-5)

Safety Data

• Hazardous Substances Data: 1044870-30-5(Hazardous Substances Data)

Upstream product

• 1545025-44-2 2-amino-4,6-dimethoxybenzonitrile 
• 1599437-13-4 N-(2-bromo-3,5-dimethoxybenzene)-2,2,2-trifluoroacetamide 
• 85657-94-9 N-(3,5-dimethoxyphenyl)-2,2,2-trifluoroacetamide 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 21577-57-1 2-amino-4,6-dimethoxybenzoic acid 
• 10272-07-8 3.5-dimethoxyaniline 
• 40891-33-6 3,5-dimethoxyaniline hydrochloride 
• 21544-81-0 4,6-dimethoxyindoline-2,3-dione 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 63920-73-0 2-amino-4,6-dimethoxybenzamide 

Downstream Products

• 1044870-39-4 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazoline-4-one 

Relevant articles and documents

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Bromodomain-containing protein 4 (BRD4) is an attractive epigenetic target in human cancers. Inhibiting the phosphorylation of BRD4 by casein kinase 2 (CK2) is a potential strategy to overcome drug resistance in cancer therapy. The present study describes the synthesis of multiple BRD4–CK2 dual inhibitors based on rational drug design, structure–activity relationship, and in vitro and in vivo evaluations, and 44e was identified to possess potent and balanced activities against BRD4 (IC50 = 180 nM) and CK2 (IC50 = 230 nM). In vitro experiments show that 44e could inhibit the proliferation and induce apoptosis and autophagy-associated cell death of MDA-MB-231 and MDA-MB-468 cells. In two in vivo xenograft mouse models, 44e displays potent anticancer activity without obvious toxicities. Taken together, we successfully synthesized the first highly effective BRD4–CK2 dual inhibitor, which is expected to be an attractive therapeutic strategy for triple-negative breast cancer (TNBC).

Based on BRD4 inhibitor RVX - 208 of the derivative and its preparation method and application (by machine translation)

The invention discloses a method based on BRD4 inhibitor RVX - 208 of the derivative and its preparation method and application. Derivatives of the structure shown in formula I. The preparation method comprises: type 8 compound of formula 9 compound reaction, [...] 10 compound; type 10 compounds with malonic acid, d di-acid or fifth heavenly stem II acid after the reaction, with vinyl carbonate, 2 - halo of isobutyric acid or 4 - halo [...] butyric acid reaction; or, the type 10 compound directly with ethylene carbonate, 2 - halo of isobutyric acid or 4 - halo [...] butyric acid reaction. The invention also provides its application. The present invention provides based on BRD4 inhibitor RVX - 208 of the derivatives, can improve the activity or at the same time reducing cholesterol lowering cholesterol and triglyceride levels. (by machine translation)

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.